Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 5/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 6/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3881744 | 0.81 | SRC (0.40) | SRCLRRK2PARP1EGFRERBB2 | |
| SCHEMBL2632169 | 0.81 | SRC (0.44) | SRCLRRK2PARP1EGFRERBB2 | |
| SCHEMBL4745808 | 0.81 | EGFR (0.43) | SRCLRRK2EGFRERBB2 | |
| SCHEMBL24009012 | 0.78 | MAP2K1 (0.56) | SRCEGFRERBB2RAF1MAP2K1 | |
| SCHEMBL3887019 | 0.78 | SRC (0.43) | SRCLRRK2EGFRERBB2RAF1 | |
| SCHEMBL3880868 | 0.78 | SRC (0.38) | SRCLRRK2PARP1EGFRERBB2 | |
| SCHEMBL3881477 | 0.78 | SRC (0.36) | SRCLRRK2PARP1EGFRERBB2 | |
| SCHEMBL3886350 | 0.77 | ALDH1A1 (0.39) | SRCLRRK2EGFRERBB2 | |
| SCHEMBL13955657 | 0.77 | SRC (0.44) | SRCLRRK2PARP1EGFRERBB2 | |
| SCHEMBL3883610 | 0.77 | SRC (0.38) | SRCLRRK2PARP1EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771443-B1 | QUINOLINE THIAZOLINONES WITH CDK-1 ANTIPROLIFERATIVE ACTIVITY | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | disclosed |
| US-7250515-B2 | Thiazolinone 3,4-disubstituted quinolines | HOFFMAN-LA ROCHE INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250515-B2 | Thiazolinone 3,4-disubstituted quinolines | HOFFMAN-LA ROCHE INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250515-B2 | Thiazolinone 3,4-disubstituted quinolines | HOFFMAN-LA ROCHE INC. (US) | 2007-07-31 | — | — | US | disclosed |
| CN-1976927-A | Quinoline thiazolinone compound | HOFFMANN LA ROCHE (CH) | 2007-06-06 | — | — | CN | disclosed |
| EP-1771443-A1 | QUINOLINE THIAZOLINONES WITH CDK1 ANTIPROLIFERATIVE ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006002828-A1 | QUINOLINE THIAZOLINONES WITH CDK1 ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-12 | — | — | WO | disclosed |
| US-20060004046-A1 | Thiazolinone 3,4-disubstituted quinolines | CHEN LI | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004046-A1 | Thiazolinone 3,4-disubstituted quinolines | CDK1, CDK17, CDK14 | SRC 1014/4885LRRK2 1506/4885PARP1 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.